STAT3-IN-1

Catalog No.S0818 Batch:S081801

Print

Technical Data

Formula

C28H29NO6
Molecular Weight 475.53 CAS No. 2059952-75-7
Solubility (25°C)* In vitro DMSO 95 mg/mL (199.77 mM)
Ethanol 5 mg/mL (10.51 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
1.18mg/ml Taking the 1 mL working solution as an example, add 50 μL of 23.6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.25mg/ml Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description STAT3-IN-1 (compound 7d) is an excellent, selective and orally active inhibitor of STAT3 with IC50 of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 induces apoptosis of tumor cells.
Targets
STAT3 [1]
(in HT29 cells)		 STAT3 [1]
(in MDA-MB 231 cells)
1.82 μM 2.14 μM

Protocol (from reference)

Selleck's STAT3-IN-1 has been cited by 3 publications

Homeostatic cytokines reciprocally modulate the emergence of prenatal effector PLZF+CD4+ T cells in humans [ JCI Insight, 2023, 8(22)e164672] PubMed: 37856221
Advanced glycation end products regulate the receptor of AGEs epigenetically [ Front Cell Dev Biol, 2023, 11:1062229] PubMed: 36866277
FcγRIIB potentiates differentiation of myeloid-derived suppressor cells to mediate tumor immunoescape [ Theranostics, 2022, 12(2):842-858] PubMed: 34976216

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.